Business
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platformLehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that George Kemble, PhD will serve as a Senior Scientific Advisor. Dr. Kemble is a veteran biotech executive and scientist
About this update from Sagimet Biosciences Inc. - Series A
[{"type":"image","alt":"CancerVAX, Inc","displaySize":"","headline":null,"caption":"CancerVAX, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/552f538f088059dc2388d649ddd505fa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w7Mi1dqXoFLTuH__5YzRfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/552f538f088059dc2388d649ddd505fa","width":300,"height":55}},"lazy":false},{"type":"text","content":"Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform","length":148,"tagName":"p"},{"type":"text","content":"Lehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that George Kemble, PhD will serve as a Senior Scientific Advisor.","length":296,"tagName":"p"},{"type":"text","content":"Dr. Kemble is a veteran biotech executive and scientist with a specialty focus in the areas of virology, vaccines and small molecule biologics. Dr. Kemble is currently the Chairman of the Board at Sagimet Biosciences Inc. (NASDAQ: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors for cancer treatment, liver fibrosis, acne and other diseases. He joined Sagimet in August 2011 as its chief scientific officer and served as CEO from October 2015 until October 2022, when he transitioned to the role of executive chairman. In May 2025, Dr. Kemble moved into the role of non-executive Chair of the Board. At Sagimet, he directed medicinal chemistry, research, translational and CMC groups, and worked on several programs including the lead product candidate, denifanstat.","length":823,"tagName":"p"},{"type":"text","content":"Prior to Sagimet, Dr. Kemble served as the senior vice president of R&D and head of research at MedImmune, Inc., a subsidiary of AstraZeneca PLC. During his tenure, he was responsible for a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble...